277 related articles for article (PubMed ID: 15142630)
1. Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer.
Kim DW; Choy H
Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):11-20. PubMed ID: 15142630
[TBL] [Abstract][Full Text] [Related]
2. Rationale for investigation of epidermal growth factor receptor inhibitors in definitive treatment of locally advanced non-small cell lung cancer and head and neck cancer.
Choy H; Kim DW
Semin Respir Crit Care Med; 2004; 25 Suppl 1():33-43. PubMed ID: 16088519
[TBL] [Abstract][Full Text] [Related]
3. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
Langer CJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):991-1002. PubMed ID: 14967461
[TBL] [Abstract][Full Text] [Related]
4. New molecular targeted therapies integrated with radiation therapy in lung cancer.
Provencio M; Sánchez A; Garrido P; Valcárcel F
Clin Lung Cancer; 2010 Mar; 11(2):91-7. PubMed ID: 20199974
[TBL] [Abstract][Full Text] [Related]
5. EGFR inhibitors with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer.
Xu Y; Zhang Y; Ma S
Lung Cancer; 2011 Sep; 73(3):249-55. PubMed ID: 21641672
[TBL] [Abstract][Full Text] [Related]
6. Is there a role for cetuximab in non small cell lung cancer?
Morgensztern D; Govindan R
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4602-5. PubMed ID: 17671149
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
Raben D; Helfrich B; Bunn PA
Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632
[TBL] [Abstract][Full Text] [Related]
8. Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors.
Ochs JS
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):941-9. PubMed ID: 14967454
[TBL] [Abstract][Full Text] [Related]
9. EGFR inhibition in NSCLC: the emerging role of cetuximab.
Herbst RS
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S41-51. PubMed ID: 19780245
[TBL] [Abstract][Full Text] [Related]
10. Combination epidermal growth factor receptor inhibition and radical radiotherapy for NSCLC.
Rogers SJ; Harrington KJ; Eccles SA; Nutting CM
Expert Rev Anticancer Ther; 2004 Aug; 4(4):569-83. PubMed ID: 15270661
[TBL] [Abstract][Full Text] [Related]
11. Targeting the epidermal growth factor receptor in non-small cell lung cancer.
Herbst RS; Bunn PA
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5813-24. PubMed ID: 14676101
[TBL] [Abstract][Full Text] [Related]
12. Integration of EGFR inhibitors and conventional chemotherapy in the treatment of non-small-cell lung cancer.
Pennell NA
Clin Lung Cancer; 2011 Nov; 12(6):350-9. PubMed ID: 21723791
[TBL] [Abstract][Full Text] [Related]
13. Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.
Barlési F; Tchouhadjian C; Doddoli C; Villani P; Greillier L; Kleisbauer JP; Thomas P; Astoul P
Fundam Clin Pharmacol; 2005 Jun; 19(3):385-93. PubMed ID: 15910663
[TBL] [Abstract][Full Text] [Related]
14. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
Ciardiello F; Tortora G
Clin Cancer Res; 2001 Oct; 7(10):2958-70. PubMed ID: 11595683
[TBL] [Abstract][Full Text] [Related]
15. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
Crawford J
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
[TBL] [Abstract][Full Text] [Related]
16. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
17. Targeted agents in non-small cell lung cancer (NSCLC): clinical developments and rationale for the combination with thoracic radiotherapy.
Koh PK; Faivre-Finn C; Blackhall FH; De Ruysscher D
Cancer Treat Rev; 2012 Oct; 38(6):626-40. PubMed ID: 22196919
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor tyrosine kinase inhibitors: evolving role in the treatment of solid tumors.
Krozely P
Clin J Oncol Nurs; 2004 Apr; 8(2):163-8. PubMed ID: 15108418
[TBL] [Abstract][Full Text] [Related]
19. Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.
Wang J; Xia TY; Wang YJ; Li HQ; Li P; Wang JD; Chang DS; Liu LY; Di YP; Wang X; Wu WZ
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e59-65. PubMed ID: 21345607
[TBL] [Abstract][Full Text] [Related]
20. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
Sequist LV; Bell DW; Lynch TJ; Haber DA
J Clin Oncol; 2007 Feb; 25(5):587-95. PubMed ID: 17290067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
